Table 3.
Summary of included studies
| Country | Reference | Study type | Study time period | Study location | Incidence rate (cases/100 000) |
|---|---|---|---|---|---|
| Albania |
Harxhi et al. 2010 [9] |
Case reports |
1997-2005 |
Tirana, Albania |
1.15 |
| Belarus |
Pankratov et al. 2006 [4] |
Review |
1996-2004 |
Belarus (National) |
41 |
| Bulgaria |
European Centre for Disease Control 2011 [6] |
Surveillance report |
2009 |
Bulgaria (National) |
5.5 |
| Czech |
European Centre for Disease Control 2011 [6] |
Surveillance report |
2009 |
Czech (National) |
6.6 |
| Estonia |
European Centre for Disease Control 2011 [6] |
Surveillance report |
2009 |
Estonia(National) |
4.2 |
| Hungary |
Ponyai et al. 2010 [10] |
Case reports |
2005 – 2008 |
Department of Dermatology, Venereology, Semmelweis University |
5.1 |
| Latvia |
European Centre for Disease Control 2011 [6] |
Surveillance report |
2009 |
Latvia (National) |
7.3 |
| Lithuania |
European Centre for Disease Control 2011 [6] |
Surveillance report |
2009 |
Lithuania (National) |
9.7 |
| Poland |
Majewski and Rudnicka 2007 [11] |
Case reports |
2005-2006 |
Warsaw, Poland (National) |
2.46 |
| Romania |
Institutul de Sanatate Publica 2008 [8] |
Surveillance report |
2007 |
Romania (National) |
25.71 |
| Slovakia |
European Centre for Disease Control 2011 [6] |
Surveillance report |
2009 |
Slovakia (National) |
5.5 |
| Slovenia |
European Centre for Disease Control 2011 [6] |
Surveillance report |
2009 |
Slovenia (National) |
2.3 |
| Turkey | Asturk et al. 2001 [5] | Surveillance review | 1991-2000 | Turkey (National) | 4.95 |